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Abstract
Renal cell carcinoma (RCC) comprises a heterogenous group of tumors. Traditionally, papil-
lary RCC (pRCC) is associated with a favorable outcome compared to clear cell RCC
(ccRCC), while other series report equivalent or worse prognosis. In this paper we compara-
tively evaluate outcome of pRCC versus ccRCC in two large multi-institutional databases
(cohort study), including distribution of pRCC subtypes 1 and 2. Retrospective data of 1,943
surgically treated pRCC patients from 17 European/ North American centers between
1984–2015 were compared to 5,600 ccRCC patients from a database comprising 11 Euro-
pean/ North American centers (1984–2011). Median follow-up was 64.6 months. Differ-
ences between pRCC, subtypes, and ccRCC were compared with t-tests, Chi^2-tests, and
exact Fisher tests. Cancer-specific mortality was analyzed with cumulative incidence curves
and Cox cause-specific hazard models. The robustness of our results was examined with
sensitivity analyses. We present that cancer-specific mortality rates and variables as stage,
lymph node, and distant metastasis differ significantly between groups. Furthermore, we
demonstrate that patients with non-metastatic pRCC had a significantly better cancer-spe-
cific mortality (HR 0.76, p = 0.007), when compared to ccRCC. Additionally, pRCC type 2
versus ccRCC exhibited no difference in cancer-specific mortality (HR 0.9, p = 0.722),
whereas pRCC type 1 versus ccRCC displayed a risk of death reduced by 69% (p = 0.044).
Taken together, outcome of pRCC versus ccRCC varies significantly in non-metastatic
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disease. Furthermore, pRCC type 2 exhibited no difference in cancer-specific mortality,
whereas pRCC type 1 displayed a significantly reduced risk of death. Consequently, there is
urgent need to respect histopathological entities and their subtypes, when assigning follow-
up or targeted therapy to RCC patients.
Introduction
Renal cell carcinoma (RCC) comprises a broad spectrum of malignancies, with indolent to
very aggressive clinical behavior [1, 2]. Recently, the International Society of Urological
Pathology (ISUP) added five new and three emerging RCC entities [3], further expanding the
spectrum of renal tumors.
Papillary RCC (pRCC) is a heterogeneous disease with two morphologic groups (pRCC
type 1 and 2) [4]. PRCC type 1 is a low-grade tumor with scanty basophilic cytoplasm, whereas
type 2 displays high-grade features with pseudo-stratified tumor cell nuclei with bulky eosino-
philic cytoplasm [5]. At ISUP conference there was agreement that pRCC subtyping is of value
[3]. Some authors consider (oncocytic) pRCC type 3, which is, however, not generally
accepted.
Furthermore, pRCC subtypes (type 1 and 2) were recently shown to be biologically distinct
[6, 7]. Accordingly, RCC histopathology classification has been confirmed by (cyto)genetic
analyses, with pRCC showing trisomy of chromosomes 7 and 17 and loss of chromosome Y,
whereas clear cell RCC (ccRCC) frequently displays deletion of chromosome 3p and mutation
of VHL gene [2]. Knowledge of these underlying molecular mechanisms has allowed for
design of targeted agents such as tyrosine kinase or mTOR inhibitors, which, besides immuno-
therapy, are currently the hallmarks of systemic therapy in metastatic RCC [8].
Traditionally, pRCC is associated with a favorable prognosis as compared to ccRCC [9–12].
However, in other series, pRCC has equivalent or worse outcome than ccRCC [13–15].
Regarding pRCC subtype outcome, few studies contained inconsistent results [5, 7, 16–18].
Given this situation, our study will increase the understanding of oncological outcome of
pRCC, pRCC subtypes and ccRCC and help to assign follow-up or targeted therapy for RCC
patients.
Patients and methods
Design, patients, and pathologic evaluation
Clinical and pathological data of patients (n = 2,325) who underwent radical or partial
nephrectomy for pRCC from 17 academic/ non-academic centers worldwide (14 European/
three North American centers, time period 1984–2015) were consecutively pooled in a retro-
spective database, whereby not all centers encompassed the entire period. In eight centers
(seven European, one North American center; n = 962) subtyping of pRCC was performed. A
distribution into the pRCC subtypes 1 and 2 was available since their inclusion in the WHO
classification in 2004 (n = 547) [2]. For direct comparison with ccRCC, the retrospective Col-
laborative Research on Renal Neoplasms Association (CORONA) database was used, compris-
ing 7,639 ccRCC from 11 academic/ non-academic centers (nine European, two US centers;
1984–2011). Patients under 18 years of age (n = 7) and patients with bilateral disease (n = 879)
were excluded. Two centers comprising 1,374 patients and 12 patients from different centers
were excluded due to inconclusive data. Additionally, 149 patients were excluded because of
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missing co-variables (stage or grade). Finally, clinical and pathological data of 7,543 patients
(pRCC n = 1,943, ccRCC n = 5,600) were analyzed. In 429 cases, pRCC was classified in pRCC
subtype 1 (n = 210) or 2 (n = 219). Eight cases with histopathological assessment of a combina-
tion of two subtypes were excluded in pRCC subtype analyses. Patients were separated in non-
metastatic/ metastatic disease; patients with pathological lymph node invasion were assigned
to the metastatic disease group. The reporting of the study has been conducted on the STROBE
statement [19].
Surgical specimens were evaluated by genitourinary pathologists at each institution [1, 2],
whereas no central pathology review was performed. Tumor stage was readjusted according to
the TNM classification of malignant tumors of 2009 [20]. Preoperative staging of patients
included abdominal CT or MRI, chest imaging, serum chemistry; bone scan and/ or brain
imaging was performed when indicated by symptoms. No patient received (neo)adjuvant ther-
apy. In metastatic disease or recurrence different therapeutic approaches in accordance with
current guidelines were used. Cause of death was determined by treating physicians, chart
review or death certificate. Approval of the study was obtained from the ethics committee of
the State Medical Board Brandenburg, Germany, the ethics committee of the University Hos-
pital Frankfurt, Goethe-University, Germany (#4/09), the local ethics committee of the Faculty
Hospital Plzen and Faculty of Medicine Plzen, Charles University, Prague, Czech Republic, the
Medical Ethics Committee II of the Faculty of Medicine Mannheim, University of Heidelberg,
Germany (#2014-811R-MA), the ethics committee of the State Medical Board Westfalen-
Lippe and the Faculty of Medicine University of Muenster, Germany (#2015-506-f-S), San Raf-
faele Ethics Committee, University Vita-Salute San Raffaele, Milan, Italy (#2007/29082007/
V3), the ethical committee of the University of Heidelberg, Germany (#206/2005), the local
human research ethics committee of the Medical Faculty of the University of Wuerzburg, Ger-
many, the institutional review board of Weill Cornell Medical College, New York, NY, USA
(#1007011131), UT Southwestern Institutional Review Board, Dallas, TX, USA, the Washing-
ton University in St. Louis Institutional Review Board, St. Louis, MO, USA (#201102423),
the ethics committee of the Technical University of Dresden, Germany (EK 269072014), the
ethics committee of the Medical University of Vienna and Vienna General Hospital, Austria,
and the ethics committee of the Medical University of Graz, Austria. In most centers, written
consent was obtained from the patients. In very few centers and permitted by the institutional
review board/ local ethics committee, oral consent was obtained and documented in the
patient chart.
Outcome measurements and statistical analysis
Study end point was cancer-specific mortality (CSM). Group differences have been evaluated
using t-tests for continuous and Chi^2-tests for nominal variables. For comparison of nominal
variables between pRCC subtypes, exact Fisher tests with Monte Carlo computation of p-
values were used. To illustrate CSM, cumulative incidence curves (CIC) and univariate Cox
cause-specific hazard models were computed. To investigate the role of histological subtype as
an independent prognostic factor, we used multivariate Cox models, adjusting for age as con-
tinuous variable and sex, Fuhrman grade and stage as nominal variables. A first multivariate
analysis was used to assess the differences in survival between pRCC and ccRCC. To compare
survival between pRCC subtypes and ccRCC, we used a second analysis including dummy var-
iables to indicate the patient affiliation to one of four groups (ccRCC, pRCC, pRCC type 1/2).
To examine the robustness of the results, sensitivity analyses were conducted, restricting either
time frames or centers, which had been included in the main analysis. Finally, multi-collinear-
ity between predictors was checked by calculating corresponding variance inflation factors.
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A p-value <0.05 was considered significant. Descriptive and inferential statistics were per-
formed as complete case analyses respective to prognostic factors of multivariate models. Sta-
tistical analysis was performed in R (version 3.2.3; R package ‘survival’) [21].
Results
Survival of patients was calculated from time of renal surgery. Median follow-up was 64.6
months (95%CI 63.0–67.0), mean age of the patients was 61.8 years (range: 18.0–93.2). In non-
metastatic disease, 5-year cumulative incidence rates (CIR) for dying of cancer for pRCC ver-
sus ccRCC and pRCC type 1 versus 2 were 6.4% versus 9.5% and 2.9% versus 8.0%. In meta-
static disease, 5-year CIR for pRCC versus ccRCC was 64.9% versus 73.9%. Though
comprising a relatively small series of patients, differences between the subgroups of pRCC
were more apparent, with 5-year CIR for pRCC type 1 versus 2 of 20.9% and 68.0%. Clinical
and pathological features of patients are summarized in Tables 1 and 2.
The pRCC cohort exhibited more male patients than ccRCC cohort, presented with lower
tumor stages at diagnosis and exhibited more patients with regional lymph node metastasis,
but fewer patients with distant metastasis (Table 1). Patients with pRCC type 2 exhibited
higher stage and grade and more regional lymph node/ distant metastases than patients with
type 1 (Table 2).
CIC and univariate survival analysis are depicted in Fig 1 and Table 3.
Multivariate Cox analyses (Table 3) revealed that patients suffering from non-metastatic
pRCC significantly correlated with reduced risk of cancer specific death (HR 0.76, p = 0.007)
compared to ccRCC. Apart from pRCC, age, sex, stage, grade and pRCC type 1 were identified
as independent predictors. PRCC type 1 (versus ccRCC) displayed a risk of death reduced by
69% (p = 0.044). PRCC type 2 (versus 1) displayed a HR of 2.9, indicating a clear coherence
despite a non-significant p-value. Nearly no difference in CSM between pRCC type 2 and
ccRCC (HR 0.9, p = 0.722) was demonstrated. We found our results to be robust when we
excluded the time frame before pRCC subtyping was included in the WHO classification and
centers not differentiating between pRCC subtypes.
In metastatic disease, only stage and grade were identified as independent predictors of
CSM. PRCC and pRCC type 1 versus ccRCC displayed a reduced risk of death by 18% and
71%, whereas pRCC type 2 versus 1 revealed a 3.51 times greater risk, though no statistical sig-
nificance was reached. Similar to non-metastatic disease, no difference in CSM between meta-
static pRCC type 2 and ccRCC was observed. Furthermore, when the analyses were restricted
to the post tyrosine kinase inhibitor era, pRCC type 2 versus 1 revealed a 4.63 times greater
risk of death (p = 0.044) (Table 4).
Finally, variance inflation factors for all covariates were<1.1. Hence, any relevant collinear-
ity effects can be ruled out.
Discussion
We comparatively evaluated the outcome of pRCC versus ccRCC in two large multi-institu-
tional databases, including distribution of pRCC subtypes 1 and 2. Our findings concerning
CSM rates and group differences agree with previous publications. Studies differentiating met-
astatic and non-metastatic disease displayed longer 5-year CSS rates for pRCC versus ccRCC
in non-metastatic disease [14, 22, 23]. In metastatic disease, information differs: where our
study showed better CSM rates for pRCC than ccRCC, other studies displayed equal [14] or
worse [22] CSS rates in pRCC. In metastatic pRCC subtypes, probably due to low patient num-
bers, no 5-year CSM rates are available. Consequently, we are the first group to present such
data. Equal to our results, former studies revealed that pRCC (versus ccRCC) displayed more
Renal cell carcinoma subtype outcome
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male patients and lower tumor stages [9, 10, 12–15, 22–24]. Our results that pRCC harbor
more regional lymph node metastasis but less distant metastasis at time of diagnosis are in
accordance with previous studies [9, 10, 12, 13, 22–24]. Again similar to our data, patients with
pRCC type 2 presented with higher tumor stages, higher grades, more regional lymph node
metastases, and more distant metastases [4, 5, 7, 16, 23, 25, 26], compared to patients with
pRCC type 1. In conclusion, the results are most likely determined by the underlying tumor
biology.
Substantially less consistent is the situation regarding outcome of pRCC: our results are in
line with the traditional hypothesis that pRCC is associated with a favorable prognosis com-
pared to ccRCC. In the largest study published to date, 2,278 pRCC patients, 13,841 ccRCC
patients and 1,486 patients with other RCC entities showed histopathology significantly associ-
ated with CSS on multivariate analysis. Here, patients with pRCC histology had improved
Table 1. Summary of clinical and pathological features and group differences between papillary renal cell carcinoma (pRCC) and clear cell renal
cell carcinoma (ccRCC) (whole cohort, n = 7,543).
pRCC ccRCC whole cohort
n % n % n % p
Age at surgery 0.94
<65 years 1,096 56.4 3,166 56.5 4,262 56.5
65 years 847 43.6 2,434 43.5 3,281 43.5
All 1,943 100.0 5,600 100.0 7,543 100.0
Sex <0.001
Female 474 24.4 2,243 40.0 2,717 36.0
Male 1,469 75.6 3,357 60.0 4,826 64.0
All 1,943 100.0 5,600 100.0 7,543 100.0
T classification <0.001
pT1a 862 44.4 1,854 33.1 2,716 36.0
pT1b 433 22.3 1,347 24.1 1,780 23.6
pT2a 163 8.4 397 7.1 560 7.4
pT2b 82 4.2 134 2.4 216 2.9
pT3a 288 14.8 1,125 20.1 1,413 18.7
pT3b 75 3.9 604 10.8 679 9.0
pT3c 8 0.4 36 0.6 44 0.6
pT4 32 1.6 103 1.8 135 1.8
All 1,943 100.0 5,600 100.0 7,543 100.0
Grade 0.0021
G1 279 14.4 938 16.8 1,217 16.1
G2 1,248 64.2 3,324 59.4 4,572 60.6
G3 358 18.4 1,145 20.4 1,503 19.9
G4 58 3.0 193 3.4 251 3.3
All 1,943 100.0 5,600 100.0 7,543 100.0
Lymph node metastasis <0.001
pN0/pNx 1,800 92.6 5,390 96.2 7,190 95.3
pN+ 143 7.4 210 3.8 353 4.7
All 1,943 100.0 5,600 100.0 7,543 100.0
Distant metastasis 0.02
cM0 1,792 92.2 5,060 90.4 6,852 90.8
cM1 151 7.8 540 9.6 691 9.2
All 1,943 100.0 5,600 100.0 7,543 100.0
https://doi.org/10.1371/journal.pone.0184173.t001
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survival (HR 0.85) compared to ccRCC [9]. Similarly, in a relatively large multi-institutional
study, demonstrating histopathology as a predictor of CSM in multivariate analysis, pRCC dis-
played more favorably (HR 0.7, p = 0.024) than ccRCC [11]. Additionally, two smaller single
institution series reported significant differences in outcome between ccRCC compared to
pRCC/ chromophobe RCC (chRCC) [10] or revealed histopathology as an independent pre-
dictor of metastasis/ death [12]. However, in other series, pRCC was reported to have equiva-
lent or worse prognosis than ccRCC. In a relatively large multi-institutional study comprising
pRCC (n = 396), chRCC (n = 103), and ccRCC (n = 3,564) with a median follow-up of 43
months, TNM classification, Fuhrman grade, and ECOG performance score, but not histopa-
thology were retained as independent prognostic variables in multivariate analysis [14].
Accordingly, two single US institution series did not reveal histopathology as independent
marker of CSS [13] or differences between pRCC and ccRCC [15]. These studies reported a
shorter follow-up and/ or less patients studied than our study. In a large subgroup of patients
Table 2. Summary of clinical and pathological features and group differences between pRCC subtypes (pRCC subtypes, n = 429).
pRCC type 1 pRCC type 2 whole cohort
n % n % n % p
Age at surgery 0.06
<65 years 138 65.7 124 56.6 262 61.1
65 years 72 34.3 95 43.4 167 38.9
All 210 100.0 219 100.0 429 100.0
Sex 0.49
Female 50 23.8 46 21.0 96 22.4
Male 160 76.2 173 79.0 333 77.6
All 210 100.0 219 100.0 429 100.0
T classification <0.001
pT1a 118 56.2 74 33.8 192 44.8
pT1b 46 21.9 53 24.2 99 23.1
pT2a 18 8.6 15 6.8 33 7.7
pT2b 6 2.9 4 1.8 10 2.3
pT3a 21 10.0 52 23.7 73 17.0
pT3b 0 0.0 15 6.8 15 3.5
pT3c 0 0.0 2 0.9 2 0.5
pT4 1 0.5 4 1.8 5 1.2
All 210 100.0 219 100.0 429 100.0
Grade <0.001
G1 46 21.9 9 4.1 55 12.8
G2 140 66.7 150 68.5 290 67.6
G3 18 8.6 49 22.4 67 15.6
G4 6 2.9 11 5.0 17 4.0
All 210 100.0 219 100.0 429 100.0
Lymph node metastasis 0.01
pN0/pNx 202 96.2 197 90.0 399 93.0
pN+ 8 3.8 22 10.1 30 7.0
All 210 100.0 219 100.0 429 100.0
Distant metastasis <0.001
cM0 201 95.7 189 86.3 390 90.9
cM1 9 4.3 30 13.7 39 9.1
All 210 100.0 219 100.0 429 100.0
https://doi.org/10.1371/journal.pone.0184173.t002
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Fig 1. Cumulative incidence curves for cancer-specific mortality. A) Non-metastatic disease, papillary
renal cell carcinoma (pRCC) versus clear cell renal cell carcinoma (ccRCC); B) Non-metastatic disease,
pRCC subtypes (type 1 and type 2) versus ccRCC; C) Metastatic disease, pRCC versus ccRCC; D)
Metastatic disease, pRCC subtypes (type 1 and type 2) versus ccRCC.
https://doi.org/10.1371/journal.pone.0184173.g001
Table 3. Uni- and multivariate Cox cause-specific hazards analysis of pRCC, ccRCC, and pRCC subtypes (type 1 and type 2) and clinical/ patholog-
ical variables for the prediction of cancer-specific mortality in patients with non-metastatic and metastatic RCC.
Univariate analysis Multivariate analysis
HR 95%CI p HR 95%CI p
Patients with non-metastatic disease (M0)
Age 1.02 1.01–1.03 <0.001 1.02* 1.01–1.03 <0.001
Sex (Female vs. Male) 0.74 0.63–0.87 <0.001 0.73* 0.62–0.86 <0.001
pT (pT 3–4 vs. pT 1–2) 4.16 3.57–4.85 <0.001 3.19* 2.73–3.74 <0.001
Grade (G 3–4 vs. G 1–2) 4.78 4.1–5.57 <0.001 3.75* 3.21–4.38 <0.001
pRCC vs. ccRCC 0.61 0.5–0.75 <0.001 0.76 0.62–0.93 0.007
pRCC type 2 vs. type1 4.59 1.31–16.11 0.017 2.9 0.83–10.19 0.097
pRCC type 1 vs. ccRCC 0.2 0.06–0.62 0.005 0.31 0.1–0.97 0.044
pRCC type 2 vs. ccRCC 0.91 0.52–1.57 0.722 0.9 0.52–1.57 0.722
Patients with metastatic disease (M1)
Age 1 0.99–1.01 0.753 1* 1–1.01 0.304
Sex (Female vs. Male) 0.9 0.75–1.08 0.266 0.87* 0.72–1.05 0.135
pT (pT 3–4 vs. pT 1–2) 1.44 1.2–1.73 <0.001 1.4* 1.16–1.69 <0.001
Grade (G 3–4 vs. G 1–2) 1.49 1.26–1.77 <0.001 1.46* 1.22–1.73 <0.001
pRCC vs. ccRCC 0.85 0.7–1.04 0.108 0.82 0.67–1 0.05
pRCC type 2 vs. type1 4.39 1.04–18.61 0.045 3.51 0.83–14.85 0.088
pRCC type 1 vs. ccRCC 0.24 0.06–0.97 0.046 0.29 0.07–1.16 0.079
pRCC type 2 vs. ccRCC 1.02 0.68–1.52 0.933 1.01 0.67–1.52 0.957
* HRs are based on two different Cox models and therefore might slightly differ
https://doi.org/10.1371/journal.pone.0184173.t003
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with RCC and tumor thrombus who underwent tumor thrombectomy, pRCC was indepen-
dently associated with poor CSS in multivariate analysis (HR 1.62, p<0.05) [27]. Additionally,
in metastatic non-clear cell disease, including pRCC, outcome of patients under systemic ther-
apy is worse than in patients with ccRCC [28]. Analogous to the latter two studies, Steffens
et al. compared retrospective data of patients with pRCC (n = 565) to ccRCC (n = 4,376) with
a median follow-up of 46.7 months [22]. Multivariate analysis revealed pRCC as significant
favorable prognostic factor in localized disease (HR 0.45), but as a negative prognostic factor
in metastatic (HR 1.37) disease. Therefore, the question was raised whether these groups corre-
spond to the pRCC subtypes 1 and 2 or are characterized by other alterations. Finally, we can-
not support their result of an unfavorable outcome of metastatic pRCC, since in our metastatic
pRCC cohort, with a distribution of 76.9% being pRCC type 2 and 23.1% being type 1, pRCC
and pRCC type 1 versus ccRCC displayed a reduced risk of death, whereas no difference in
CSM between metastatic pRCC type 2 and ccRCC was observed. Therefore, it remains unclear
why the outcome of pRCC versus ccRCC varies between non-metastatic and metastatic disease
in their study, whereby the results are supported by real-life scenario on metastatic non-
ccRCC outcome [28]. Another study revealed histopathology as independent predictor of CSS
(p = 0.03) in a multivariate model, however little gain (+0.1%) in predictive accuracy was seen.
Therefore, the authors concluded that, from a statistical perspective, the various histopatholo-
gies might be included as single entity [24]. Although speculative, the predictive accuracy
would be greater, had it been possible to differentiate the included pRCC in subtypes 1 and 2.
Few other studies published contain inconsistent results regarding pRCC subtype outcome
with a maximum of 486 pRCC patients. Statistical limitations or shorter follow-up were often
present when compared to our work. Two studies retained pRCC subtype as independent
prognostic factor on multivariate analysis [5, 16], three others exhibited pRCC subtype not sig-
nificantly associated with CSS in multivariate analysis [7, 17, 26]. The largest pRCC subtype
series to date (type 1 n = 369, type 2 n = 117), comprising only patients treated with nephron-
sparing surgery for T1-3 tumors with a mean follow-up of 35 months in a retrospective multi-
institutional setting, displayed patients with pRCC type 1 with an equal risk of RCC death
compared to type 2 (HR 0.9, p = 0.89) [26]. In our slightly smaller patient cohort, comprising
429 non-metastatic and metastatic pRCC subtypes with a considerably longer follow-up, non-
metastatic pRCC type 1 (vs. ccRCC) remained as independent favorable prognostic factor of
CSM in multivariate analysis, whereas non-metastatic pRCC type 2 exhibited no difference in
Table 4. Uni- and multivariate Cox cause-specific hazards analysis of pRCC, ccRCC, and pRCC subtypes (type 1 and type 2) and clinical and path-
ological variables for the prediction of cancer-specific mortality in patients with metastatic RCC in the post tyrosine kinase inhibitor era.
Univariate analysis Multivariate analysis
HR 95%CI p HR 95%CI p
Patients with metastatic disease (M1)
Age 1 0.98–1.02 0.916 1* 0.98–1.02 0.891
Sex (Female vs. Male) 1.06 0.67–1.7 0.796 1.06* 0.66–1.71 0.815
pT (pT 3–4 vs. pT 1–2) 1.31 0.84–2.04 0.237 1.21* 0.76–1.92 0.421
Grade (G 3–4 vs. G 1–2) 1.41 0.91–2.2 0.125 1.36* 0.86–2.16 0.187
pRCC vs. ccRCC 0.89 0.58–1.36 0.579 0.86 0.56–1.34 0.514
pRCC type 2 vs. type1 5.12 1.17–22.31 0.03 4.63 1.05–20.52 0.044
pRCC type 1 vs. ccRCC 0.24 0.06–1.02 0.053 0.29 0.07–1.21 0.09
pRCC type 2 vs. ccRCC 1.27 0.7–2.27 0.431 1.34 0.74–2.42 0.33
* HRs are based on two different Cox models and therefore might slightly differ
https://doi.org/10.1371/journal.pone.0184173.t004
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CSM. Consequently, our results clearly support the ISUP conference consensus, that tumors
should be classified as type 1 and 2.
Despite academic interest, outcome of pRCC versus ccRCC matters in daily clinical prac-
tice. In non-metastatic disease, our work regards follow-up decisions: patients with pRCC type
1 should obtain a reduced follow-up scheme compared to patients with ccRCC or pRCC type
2. In metastatic disease, our data can help when assigning systemic therapy: Whereas the EAU
guideline [8] discriminates between ccRCC and non-ccRCC, based on our data, a patient with
a metastatic pRCC type 2 has a nearly equal risk of dying from this disease as a patient with a
metastatic ccRCC. Consequently, this patient needs a therapy with equal efficacy as for ccRCC.
On the other hand, a patient with a pRCC type 1 might need active surveillance with delayed
systemic therapy. Given the molecular differences of pRCC, their subtypes, and ccRCC, tar-
geted agents such as tyrosine kinase inhibitors show significantly less efficacy in tumors with
non-ccRCC including pRCC histology [28, 29]. Given mutations of the mesenchymal-epithe-
lial transition (MET) oncogene in pRCC type 1 and of fumarate hydratase (FH) in pRCC type
2 [2], targeted agents assigning MET (e.g. the recently FDA approved tyrosine kinase inhibitor
cabozantinib targeting MET, VEGFR, and AXL [30]) or FH have probably higher efficacy in
these patients. Despite the underlying tumor biology, which defines future targeted therapies,
an accurate assignment of already approved agents is also of importance. Recently, the ran-
domized phase 2 ASPEN trial showed a longer median progression-free survival in pRCC
patients treated with sunitinib compared to everolimus [31], further corroborating the need
for a more diversified histopathology-based strategy in assigning targeted agents. Additionally,
this also further underlines the necessity to obtain a renal tumor biopsy prior to definitive
treatment of metastatic RCC, in patients in whom cytoreductive nephrectomy is not being per-
formed or a former histopathology has been inconclusive.
Several limitations of our study should be noted: First, our work is based on retrospective
data and a central pathology review was not performed. Although re-classification of tumors
according to the ISUP criteria [3] possibly minimizes the risk of misclassification, central
pathology review can hardly be performed in 7,543 cases from two worldwide databases. Sec-
ond, discrimination between pRCC subtype 1 and 2 was performed in eight of 17 centers,
therefore, corresponding data were available in 429 cases. This situation reflects the real-world
scenario of pathologists, where only 59% of the respondents of the ISUP preconference survey
noted that they classified tumors according to subtypes 1 and 2 [3]. Third, variables such as
concomitant sarcomatoid differentiation or tumor necrosis were recorded in both databases,
but due to missing values of 20–30% these were not selected for further analysis, otherwise dis-
playing a maximum of 1.5% missing values. However, to date, this is the largest international
multi-institutional study of non-metastatic and metastatic pRCC, pRCC type 1 and 2, and
ccRCC with a long median follow-up.
Conclusions
Patients with non-metastatic pRCC showed a significantly reduced risk of cancer specific death,
when compared to ccRCC. Additionally, pRCC type 1 displayed a risk of death reduced by
69%, whereas pRCC type 2 exhibited no difference in CSM, which might indicate an analogous
clinical behavior of these two RCC entities. There is urgent need to consider histopathological
entities and their subtypes, when assigning follow-up or targeted therapy for RCC patients.
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